combined with other pharmaceutical
active substances" (page 11 of the description).
Linagliptin (BI 1356), a particularly preferred DPP-4
inhibitor of the present application ... DEVANSHU JOSHI
Signing Date:21.07.2022
10:49:18
enriching the art. Further, Linagliptin is characterized
by unique pharmacokinetics, such as with nonlinear
profile (less than
offering for sale, selling, importing and/or exporting the
medicinal product, Linagliptin in any form whatsoever
including Linagliptin API, Linagliptin formulation,
.
"Linagliptin Tablet ... Linagliptin + Metformin
Hydrochloride Tablets" or any "generic version" thereof
or any product sold under the trade marks/brand names
"LINARES
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
offering for sale, selling, importing and/or exporting the
medicinal product, Linagliptin in any form whatsoever
including Linagliptin API, Linagliptin formulation,
.
"Linagliptin Tablet ... Linagliptin + Metformin
Hydrochloride Tablets" or any "generic version" thereof
or any product sold under the trade marks/brand names
"LINARES
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
offering for sale, selling, importing and/or exporting the
medicinal product, Linagliptin in any form whatsoever
including Linagliptin API, Linagliptin formulation,
.
"Linagliptin Tablet ... Linagliptin + Metformin
Hydrochloride Tablets" or any "generic version" thereof
or any product sold under the trade marks/brand names
"LINARES
offering for sale, selling, importing and/or exporting the
medicinal product, Linagliptin in any form whatsoever
including Linagliptin API, Linagliptin formulation,
.
"Linagliptin Tablet ... Linagliptin + Metformin
Hydrochloride Tablets" or any "generic version" thereof
or any product sold under the trade marks/brand names
"LINARES
granted in favour
of the plaintiffs restraining the defendants from manufacturing
LINAGLIPTIN tablets and the said interim order has continued till date.
3. Summons ... parties, Defendants shall not
manufacture, sell, offer for sale and/or use
LINAGLIPTIN or LINAGLIPTIN tablets, or any
other pharmaceutical preparations or formulations
containing LINAGLIPTIN
